BACKGROUND Primary small cell of esophageal carcinoma is an aggressive tumor with no established treatment guidelines.A treatment strategy was adopted based on small cell carcinoma of the lung because of many similar ...BACKGROUND Primary small cell of esophageal carcinoma is an aggressive tumor with no established treatment guidelines.A treatment strategy was adopted based on small cell carcinoma of the lung because of many similar clinicopathological features.Here,we report one of the largest case series in a western population.AIM To review the practice of treating small cell oesophageal cancer(SCOC)with different treatment modalities treated at our institution between 2001 and 2014.METHODS A total of 28 cases of SCOC have been identified.All cases were identified with a ten-digit code known as the CHI number.Data was collected using a combination of an electronic database,case notes and the chemotherapy electronic prescribing system(chemocare).We collected information on age,gender,performance status,staging of the disease(limited stage vs extensive stage).RESULTS The results showed 17 patients(61%)were diagnosed with limited stage small cell oesophageal cancer(LS-SCOC),while 11 patients(39%)were diagnosed with extensive stage small cell oesophageal cancer(ES-SCOC).The median age at diagnosis of SCOC was 72 years(range 52-86).The median survival for patients with ES-SCOC was 7 mo(95%CI:1-12)vs LS-SCOC[median 23 mo(95%CI:14-40)],P<0.0001.Subgroup analysis of those who received treatment showed the median survival for patients who received palliative chemotherapy was 7 mo(95%CI:1.5-12),concurrent chemoradiation 45 mo(95%CI:38-)and sequential chemoradiation 20 mo(95%CI:17-25),P<0.0001.CONCLUSION Our data strongly support the use of concurrent chemoradiation in the treatment of LS-SCOC in patients who are fit with no significant comorbidity.展开更多
文摘BACKGROUND Primary small cell of esophageal carcinoma is an aggressive tumor with no established treatment guidelines.A treatment strategy was adopted based on small cell carcinoma of the lung because of many similar clinicopathological features.Here,we report one of the largest case series in a western population.AIM To review the practice of treating small cell oesophageal cancer(SCOC)with different treatment modalities treated at our institution between 2001 and 2014.METHODS A total of 28 cases of SCOC have been identified.All cases were identified with a ten-digit code known as the CHI number.Data was collected using a combination of an electronic database,case notes and the chemotherapy electronic prescribing system(chemocare).We collected information on age,gender,performance status,staging of the disease(limited stage vs extensive stage).RESULTS The results showed 17 patients(61%)were diagnosed with limited stage small cell oesophageal cancer(LS-SCOC),while 11 patients(39%)were diagnosed with extensive stage small cell oesophageal cancer(ES-SCOC).The median age at diagnosis of SCOC was 72 years(range 52-86).The median survival for patients with ES-SCOC was 7 mo(95%CI:1-12)vs LS-SCOC[median 23 mo(95%CI:14-40)],P<0.0001.Subgroup analysis of those who received treatment showed the median survival for patients who received palliative chemotherapy was 7 mo(95%CI:1.5-12),concurrent chemoradiation 45 mo(95%CI:38-)and sequential chemoradiation 20 mo(95%CI:17-25),P<0.0001.CONCLUSION Our data strongly support the use of concurrent chemoradiation in the treatment of LS-SCOC in patients who are fit with no significant comorbidity.
